Ivermectin Versus Albendazole for Chronic Strongyloidiasis
Information source: Mahidol University
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Chronic Strongyloidiasis
Intervention: Ivermectin (Drug); ivermectin (Drug); Albendazole (Drug)
Phase: Phase 3
Status: Enrolling by invitation
Sponsored by: Mahidol University Official(s) and/or principal investigator(s):
Yupin Suputtamongkol, MD, Principal Investigator, Affiliation: Mahidol University
Summary
A prospective controlled trial to compare the efficacy and safety of 7-day albendazole,
single dose ivermectin, and 2-single dose ivermectin in 72 patients with chronic
strongyloidiasis will be conducted at Siriraj Hospital, Bangkok, Thailand.
Clinical Details
Official title: Efficacy and Safety of Ivermectin Versus Albendazole for Chronic Strongyloidiasis
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: cure rate
Secondary outcome: safety
Eligibility
Minimum age: 18 Years.
Maximum age: 90 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Patients with positive strongyloides larva in the stool
Exclusion Criteria:
- Pregnancy
- Lactating women
- Known allergy to any study drug
Locations and Contacts
Siriraj Hospital, Bangkoknoi, Bangkok 10700, Thailand
Additional Information
Starting date: July 2008
Last updated: June 18, 2010
|
